日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Escherichia coli Uncharacterized protein yfcM (yfcM) CSB-YP303516ENV
CSB-EP303516ENV
CSB-BP303516ENV
CSB-MP303516ENV
CSB-EP303516ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Uncharacterized protein yqeK (yqeK) CSB-YP303517ENV
CSB-EP303517ENV
CSB-BP303517ENV
CSB-MP303517ENV
CSB-EP303517ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Uncharacterized protein ykfB (ykfB) CSB-YP303518ENV
CSB-EP303518ENV
CSB-BP303518ENV
CSB-MP303518ENV
CSB-EP303518ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Cell division protein ZipA (zipA), partial CSB-YP303519ENV1
CSB-EP303519ENV1
CSB-BP303519ENV1
CSB-MP303519ENV1
CSB-EP303519ENV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Thiol:disulfide interchange protein DsbG (dsbG) CSB-YP303520ENV
CSB-EP303520ENV
CSB-BP303520ENV
CSB-MP303520ENV
CSB-EP303520ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Uncharacterized protein ybdN (ybdN) CSB-YP303521ENV
CSB-EP303521ENV
CSB-BP303521ENV
CSB-MP303521ENV
CSB-EP303521ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Lysis protein S homolog from lambdoid prophage Qin (essQ) CSB-YP303522ENV
CSB-EP303522ENV
CSB-BP303522ENV
CSB-MP303522ENV
CSB-EP303522ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Uncharacterized protein ykgE (ykgE) CSB-YP303523ENV
CSB-EP303523ENV
CSB-BP303523ENV
CSB-MP303523ENV
CSB-EP303523ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Multidrug resistance-like ATP-binding protein MdlA (mdlA), partial CSB-YP303524ENV1
CSB-EP303524ENV1
CSB-BP303524ENV1
CSB-MP303524ENV1
CSB-EP303524ENV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Electron transport complex protein RnfG (rnfG), partial CSB-YP303525ENV1
CSB-EP303525ENV1
CSB-BP303525ENV1
CSB-MP303525ENV1
CSB-EP303525ENV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Uncharacterized HTH-type transcriptional regulator yagI (yagI) CSB-YP303526ENV
CSB-EP303526ENV
CSB-BP303526ENV
CSB-MP303526ENV
CSB-EP303526ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Dipeptide and tripeptide permease A (dtpA), partial CSB-YP303527ENV
CSB-EP303527ENV
CSB-BP303527ENV
CSB-MP303527ENV
CSB-EP303527ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Chaperone protein hscC (hscC) CSB-YP303528ENV
CSB-EP303528ENV
CSB-BP303528ENV
CSB-MP303528ENV
CSB-EP303528ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Hemolysin E, chromosomal (hlyE), partial CSB-YP303529ENV1
CSB-BP303529ENV1
CSB-MP303529ENV1
CSB-EP303529ENV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Uncharacterized lipoprotein yafY (yafY) CSB-YP303530ENV
CSB-EP303530ENV
CSB-BP303530ENV
CSB-MP303530ENV
CSB-EP303530ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Lipopolysaccharide biosynthesis protein wzxC (wzxC), partial CSB-YP303531ENV
CSB-EP303531ENV
CSB-BP303531ENV
CSB-MP303531ENV
CSB-EP303531ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli [Citrate [pro-3S]-lyase] ligase (citC) CSB-YP303532ENV
CSB-EP303532ENV
CSB-BP303532ENV
CSB-MP303532ENV
CSB-EP303532ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Uncharacterized HTH-type transcriptional regulator ydiP (ydiP) CSB-YP303533ENV
CSB-EP303533ENV
CSB-BP303533ENV
CSB-MP303533ENV
CSB-EP303533ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Autoinducer-2 kinase (lsrK) CSB-YP303534ENV
CSB-EP303534ENV
CSB-BP303534ENV
CSB-MP303534ENV
CSB-EP303534ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli Bifunctional protein PaaZ (paaZ) CSB-YP303535ENV
CSB-EP303535ENV
CSB-BP303535ENV
CSB-MP303535ENV
CSB-EP303535ENV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.bdspa.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×